RxDoctor Payments Data

Hai Shiuh Wang, MD

Ophthalmology · Youngstown, OHNPI 1053313551

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 56 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$407
  • Regeneron Healthcare Solutions, Inc.$245
  • Mallinckrodt Hospital Products Inc.$191
  • Apellis Pharmaceuticals, Inc.$171
  • Aerie Pharmaceuticals, Inc.$153
  • AbbVie$135
  • plus $391 from 9 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,58894%
  • Education$935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$161,931
Medicare patients
478
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$29,048
LumiganBimatoprost66$28,999
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol80$14,364
Latanoprost1,415$13,406
CombiganBrimonidine Tartrate/Timolol39$11,461
VyzultaLatanoprostene Bunod27$10,665
RocklatanNetarsudil Mesylat/Latanoprost18$8,124
Timolol Maleate286$6,613
Cyclosporine13$6,348
Travoprost21$4,809
Brimonidine Tartrate416$4,447
Dorzolamide Hcl178$3,512
Brinzolamide15$1,808
Fluorometholone24$1,713
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha145$1,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$135$69,509137 claims
Aerie Pharmaceuticals, Inc.Rocklatan$153$8,12418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →